Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 6992-6998

  Zhou, Ping ^a   Chen, Ming Hui ^a   McLeod, David ^a   Carroll, Peter R ^a   Moul, Judd W ^a   D'Amico, Anthony V ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; BIOPSY; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; FACTUAL DATABASE; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PREDICTION AND FORECASTING; PROSTATE TUMOR; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; BIOPSY; COHORT STUDIES; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 27244451002     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.2906     Document Type: Article

References (33)

1. Han M, Partin AW, Zahurak M, et al: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523, 2003
2. Shipley WU, Thames HD, Sandler HM, et al: Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 281:1598-1604, 1999
3. Albertsen PC, Hanley JA, Gleason DF, et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975-980, 1998
4. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
5. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441-1445, 1997
6. Ward JF, Blute ML, Slezak J, et al: The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170:1872-1876, 2003
7. Lee WR, Hanks GE, Hanlon A: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15:230-238, 1997
8. Sartor CI, Strawderman MH, Lin XH, et al: Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38:941-947, 1997
9. Hanlon AL, Diratzouian H, Hanks GE: Post-treatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53:297-303, 2002
10. Kuban DA, Thames H, Horwitz E, et al: Predicting outcome after PSA failure in prostate cancer patients treated by radiation: Who needs salvage therapy. Int J Radiat Oncol Biol Phys 60:S167, 2004 (suppl 1)
11. Sandler HM, Dunn RL, McLaughlin PW, et al: Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48:629-633, 2000
12. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
13. Albertsen PC, Hanley JA, Penson DF, et al: Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 171:2221-2225, 2004
14. D'Amico AV, Cote K, Loffredo M, et al: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20:4567-4573, 2002
15. Partin AW, Eisenberger MA, Sinibaldi VJ, et al: Prostate specific antigen doubling time (PSADT) predicts for distant failure and prostate cancer specific survival (PCSS) in men with biochemical relapse after radical prostatectomy (RP). Presented at the Annual Meeting of American Urologic Association, San Francisco, CA, May 8-13, 2004
16. Lubeck DP, Litwin MS, Henning JM, et al: The CaPSURE database: A methodology for clinical practice and research in prostate cancer-CaPSURE Research Panel-Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48:773-777, 1996
17. Sun L, Gancarczy K, Paquette EL, et al: Introduction to the Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in PSA-era. Urol Oncol 6:203-209, 2001
18. Soloway MS, Pareek K, Sharifi R, et al: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167:112-116, 2002
19. The Veterans Administration Cooperative Urological Research Group, Gleason DF: Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology. Philadelphia, PA, Lea & Febiger, 1977, pp 171-187
20. Lee CT, Oesterling JE: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24:389-394, 1997
21. Greene FL, Page DL, Fleming ID, et al: American Joint Committee on Cancer Manual for Staging Cancer (ed 6). New York, NY, Springer-Verlag, 2002
22. Cox JD: Consensus statement: Guidelines for PSA following radiation therapy-American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
23. Fine JP, Gray RJ: A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
24. Gaynor JJ, Feur EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
25. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
26. Berry W, Dakhil S, Modiano M, et al: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168:2439-2443, 2002
27. Ernst DS, Tannock IF, Winquist EW, et al: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone refractory prostate cancer and pain. J Clin Oncol 21:3335-3342, 2003
28. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506-2513, 1999
29. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
30. Petrylak DP, Tangen CM, Hussein MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
31. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
32. Harper ME, Pierrepoint CG, Griffiths K: Carcinoma of the prostate: Relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 20:477-482, 1984
33. Zhang PL, Rosen S, Veeramachaneni R, et al: Association between prostate cancer and serum testosterone levels. Prostate 53:179-182, 2002